Genmab — September 2019
-
yes, that made me revisit this. here is the SEC form F1 https://sec.report/Document/0001140361-19-016305/
-
and then i also thought "Risks Related to Our Relationship with Third Parties" was interesting as it says "Our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize ADCT-301."
-
Our collaboration and license agreement with Genmab requires a divestment of ADCT-301, in which Genmab has a 25% interest, following database lock for the Phase 1/2 clinical trial. The agreement sets out a defined process to facilitate the divestment of ADCT-301 by licensing the rights thereto to a third party, subject to Genmab’s right of first opportunity to negotiate to acquire ADCT-301 in full.
-
the Lundbeck Parkinson's trial a bit delayed, doesn't seem to recruit very enthusiastically https://clinicaltrials.gov/ct2/history/NCT03611569?A=2&B=3&C=merged#StudyPageTop
-
Lad os få good news så den kan søge opad igen..:-)
-
Her fortsættelsen af det sidste afsnit, EL citerede: "
This process includes the opportunity for both parties to bid for the license rights alongside third parties. Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process. Therefore, our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will apply for regulatory approval of or commercialize ADCT-301." -
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED) https://www.businesswire.com/news/home/20190909005532/en/Horizon-Therapeutics-plc-Announces-FDA-Granted-Priority/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhBsNpnJw7dvSfTyni2BOVIOrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nDlC87j5HoE75BMeA8LaVacVjEfZIyqgxRRsuxHCTK2w%3D%3D&utm_source=dlvr.it&utm_medium=twitter
-
Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
-
The multi-year collaboration will combine Tempus’ sequencing capabilities and industry-leading platform of integrated clinical and molecular data with Genmab’s state-of-the-art translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, to advance new disease targets and biomarkers that may have the potential to generate new treatments in oncology.
-
This new strategic collaboration builds upon existing service agreements between the companies. Under the terms of the collaboration agreement, the companies will jointly work on research projects that are identified by Genmab to explore novel product concepts and biomarkers.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind